MetaCap

GeoVax Labs (GOVX) vs Oragenics (OGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GeoVax Labs is the larger company by market cap ($985,459 vs $708,377), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GOVX+525.43%OGEN-68.59%
+682%+289%-104%
Oct 7, 20261 yearNov 20, 2026
GOVX+544.13%OGEN-65.57%
+575%+239%-96%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GOVX versus OGEN key metrics
MetricGOVXOGEN
Share price$1.81$0.157
Market cap$985.46K$708.38K
1-day change-5.24%-8.72%
EPS (TTM)$-15.03$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.49M—
Revenue growth (YoY)-37.06%—
Net income (latest FY)$-21.46M$-9.84M
Operating margin-869.34%—
Net margin-862.34%—
52-week high$270.60$1.11
52-week low$1.51$0.13
Distance from 52-week high-99.33%-85.86%
Analyst consensusnone—
Avg. price target upside+452.49%—
Average volume213.41K849.30K
Shares outstanding544.45K4.51M
Employees193
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Oragenics

OGEN stock →

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

GOVX vs OGEN FAQ

Which is bigger, GeoVax Labs or Oragenics?

GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $708.38K for Oragenics (OGEN).

Are GeoVax Labs and Oragenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons